Evidence overview
GLP-1 medications: what the evidence shows
Medicines such as Ozempic, Wegovy, Mounjaro, and Zepbound have changed conversations about diabetes and weight. Here is what major clinical trials and FDA labels actually say — and what they do not.
This article is for general education. It is not personal medical advice, and it is not a recommendation that you start, stop, or change any medicine. If you have questions about your own care, talk with a clinician. In an emergency, call 911.
What these medicines are
GLP-1 stands for glucagon-like peptide-1, a hormone involved in blood sugar, appetite, and how quickly the stomach empties. GLP-1 receptor agonists are prescription medicines that mimic that hormone.
Two names you will hear often, Ozempic and Wegovy, both contain semaglutide. They are not interchangeable on a label: Ozempic is approved to treat type 2 diabetes, and Wegovy is approved for chronic weight management in eligible adults, and to reduce the risk of major cardiovascular events in adults who already have cardiovascular disease and have obesity or overweight.
Mounjaro and Zepbound contain tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist, not a plain GLP-1 medicine. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management in eligible adults. Approved uses, doses, and insurance coverage can differ even when the active ingredient is related, so the brand on the label matters.
What the major trials found
The findings below are from large, peer-reviewed trials. They describe average results in the people who were studied, not a promise of what any one person will experience.
In STEP 1, published in the New England Journal of Medicine in 2021, 1,961 adults with overweight or obesity and without diabetes were assigned to weekly semaglutide 2.4 mg or placebo, along with lifestyle counseling. At 68 weeks, mean weight change was −14.9% with semaglutide and −2.4% with placebo.
In SELECT, published in 2023, 17,604 adults age 45 or older with overweight or obesity and existing cardiovascular disease, but not diabetes, were assigned to weekly semaglutide 2.4 mg or placebo. The primary endpoint — cardiovascular death, nonfatal heart attack, or nonfatal stroke — occurred in 6.5% of people on semaglutide and 8.0% of people on placebo, a 20% relative reduction (hazard ratio 0.80). In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
In SURMOUNT-1, adults with obesity, or with overweight plus at least one weight-related condition, and without diabetes, received tirzepatide or placebo for 72 weeks. Mean weight change at the 15 mg dose was −20.9%, compared with −3.1% with placebo.
In SURMOUNT-5, tirzepatide was compared directly with semaglutide over 72 weeks. Mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Head-to-head results like this help clinicians compare options; they still do not tell you which medicine, if any, is right for you.
Safety, side effects, and who should not take them
These medicines are not right for everyone. FDA prescribing information for the semaglutide and tirzepatide products includes a boxed warning about thyroid C-cell tumors observed in rodents. The medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. Whether that animal finding applies to people is not fully known, which is why the warning is on the label.
Stomach and intestinal side effects are common, including nausea, vomiting, diarrhea, and constipation. Labels also discuss other serious risks, which is one reason these medicines require a prescription and follow-up, not informal or unmonitored use.
The FDA has also warned about compounded versions of these drugs that are not FDA-approved, including concerns about quality, dosing errors, and safety. If you are considering one of these medicines, ask your clinician about an approved product and a follow-up plan.
How to read this if you are a patient
The studies above are encouraging, and they are also specific: they enrolled defined groups of people, used particular doses, and followed patients closely. A medicine that helped many people in a trial can still be a poor fit because of other health conditions, side effects, cost and access, or personal preference. Weight can also return after a medicine is stopped, so long-term planning belongs in the same conversation as starting treatment.
Advanced Medical Care of Hudson County does not run a separate weight-loss or GLP-1 program. If you want to talk about whether one of these medicines might be appropriate for you, or about nutrition, diabetes, or blood pressure care more broadly, you are welcome to book a visit or call us. We can help you think it through in the context of your overall health.
Quick answers
What are GLP-1 medications?
GLP-1 receptor agonists are prescription medicines that mimic a hormone involved in blood sugar, appetite, and digestion. Familiar brand names include Ozempic and Wegovy (semaglutide). Mounjaro and Zepbound (tirzepatide) act on both GIP and GLP-1 receptors, so they are dual agonists rather than plain GLP-1 medicines. Approved uses differ by brand and are listed on each FDA label.
What did major studies show about weight and heart risk?
In the STEP 1 trial, weekly semaglutide 2.4 mg led to a mean 14.9% weight loss at 68 weeks, compared with 2.4% with placebo. In SELECT, among 17,604 adults with overweight or obesity and existing cardiovascular disease but not diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% relative to placebo (6.5% vs 8.0%). In SURMOUNT-1, tirzepatide 15 mg led to a mean 20.9% weight loss at 72 weeks, compared with 3.1% with placebo. In SURMOUNT-5, tirzepatide led to a mean 20.2% weight loss versus 13.7% with semaglutide at 72 weeks.
Are Ozempic and Wegovy the same medicine?
Both contain semaglutide, but they are approved for different uses and doses. Ozempic is approved to treat type 2 diabetes. Wegovy is approved for chronic weight management in eligible adults and to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. A clinician should decide whether a medicine and dose are appropriate for you.
What are the main risks?
FDA labels for these medicines carry a boxed warning about a risk of thyroid C-cell tumors seen in rodents, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Stomach and intestinal side effects such as nausea, vomiting, diarrhea, and constipation are common. Labels also describe other serious risks. These medicines are not right for everyone, and they require a prescription and medical follow-up.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. March 8, 2024. FDA announcement
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA compounding and unapproved GLP-1 page
- See also the current FDA prescribing information (labels) for Ozempic, Wegovy, Mounjaro, and Zepbound, including boxed warnings and contraindications.
Want to talk this through?
Book a visit or call the office. We can discuss your questions in the context of your overall health.


